ESR1 and breast carcinoma: The resulting PROTAC, ZD12, showed potent antiproliferative effects and complete ERα degradation even at 10 nM in a broad spectrum of ERα+ breast cancer cells, including tamoxifen-resistant and ERα mutant cell lines.